A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01)

Sequential administration of the association of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel could be better tolerated than the association of an anthracycline and paclitaxel while having a similar antitumour effect. 69 patients with advanced breast cancer previously untreate...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Riccardi, A, Pugliese, P, Danova, M, Brugnatelli, S, Grasso, D, Giordano, M, Bernardo, G, Giardina, G, Fava, S, Montanari, G, Pedrotti, C, Trotti, G, Rinaldi, E, Poli, M A, Tinelli, C
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2001
Témata:
Regular Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2364040/
https://ncbi.nlm.nih.gov/pubmed/11461067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1054/bjoc.2001.1897
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky